Yesterday the FDA announced not just one but two approvals in the diabetes device arena. Senseonics received approval for their Eversense implantable CGM while Tandem (NASDAQ: TNDM) received approval for their t:slim X2™ Insulin Pump with Basal-IQ™ technology. Of the two approvals we see the Tandem as more significant as it puts them on a path to compete head on with insulin pump market leader Medtronic (NYSE: MDT).
A few quick comments as many see this as the dawn of new era at the FDA and it may well be. After years of moving at glacial . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.